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We report a nonsmoker adult with histologically proven pulmonary Langerhans cell
histiocytosis (PLCH) with bronchial hyperresponsiveness (BHR) presenting with spontaneous
pneumothorax. An 18-year-old, nonsmoker student had shortness of breath for a decade.
PFTs and lung volume study (obtained one month post-operation) showed a mild obstructive
airway with bronchodilator response and a decreased DLco with a positive methacholine
challenge test (PC20o8mg/ml). Chest radiograph revealed right-sided pneumothorax and
diffuse reticular infiltrates. HRCT revealed scattered, thin-walled lung cysts in all lobes
without sparing of the costophrenic angles. The patient underwent a thoracotomy for
wedge resection and the diagnosis of PLCH was confirmed by a demonstration of the
accumulated Langerhans cells histiocytes (positive CD1a) in lung tissue. Pneumothorax was
managed by bleblectomy and pleurodesis. This case report demonstrates BHR concurrent
with PLCH on a nonsmoker patient. The combination of BHR and PLCH may confer a
detrimental synergistic effect on the respiratory symptoms, deterioration of lung function,
lung cysts and hence spontaneous pneumothorax on these patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pulmonary Langerhans cell histiocytosis (PLCH), an uncom-
mon disorder of young adults, characterized by a mono-Elsevier Ltd. All rights reserved.
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com (W. Suttithawil).clonal proliferation and infiltration of multiple organs by
activated Langerhans cells, one of the family of dendritic
cells1,2 without known genetic factor.2–4 Even though the
association between PLCH and cigarette smoking seems
strong, the occurrence of this disease among young children
and nonsmoker adults needs explanations.4 Common organ
involvement includes lungs, bone, skin, pituitary gland,
ARTICLE IN PRESS
Figure 1 High resolution computed tomography (HRCT) of the
chest reveals scattered thin-walled cysts and bullae in all lobes
including at the costophrenic angle regions without intrathor-
acic lymph nodes enlargement. The largest bullae measuring
2.3 cm in diameter and presenting on subpleural location.
Figure 2 Spirometry, obtained one month post-operation,
demonstrates a moderate obstructive pattern with bronchodi-
lator response with a positive methacholine challenge test
(PC20o8mg/ml).
W. Suttithawil et al.62liver, lymph nodes and thyroid glands.3 The diagnosis was
generally made by the demonstration of Birbeck granules in
the lesional cells on electron microscopy or the presence of
CD1a antigenic determinants on the surface of cells by
immunohistochemistry technique. The etiology of LCH
remains unestablished to date. Pathologically, there is an
accumulation of activated histiocytes, organizing into
granulomas, particularly involving the distal bronchioles.3,4
Even though the disease characteristically affects the small
airways and can produce clinical manifestations mimicking
asthma,5 there has never been a report, demonstrating BHR
and its impact on these patients. We describe an interesting
case of PLCH on nonsmoker with positive MCT, presenting
with spontaneous pneumothorax.
Case report
An 18-year-old man had a decade long-history of progressive
dyspnea, chest pain, cough and paroxysms of wheezes. He
had been diagnosed to have asthma and received asthmatic
medications for 4 years. Over the past few years, he had
more frequent episodes of chest tightness, pleuritic chest
pain, abdominal pain, anorexia, and weight loss. Chest
examination revealed decreased breath sound on the right-
sided and wheezes at both lower lungs. He had no finger
clubbing and skin lesions. Laboratory studies showed a
hemoglobin of 14.6 g/dL, a WBC count of 11.1 109/L
(65.5% neutrophils, 5.8% eosinophil), alpha-1 antitrypsin
level of 183mg/dL (normal values: 90–200) and normal urine
analysis. Skin prick tests showed a positive reaction to
house-dust-mite. Radiographs of the chest revealed right-
sided pneumothorax with reticular infiltrates in bilateral
lungs. The HRCT of the chest revealed scattered, variable-
sized thin-walled lung cysts, all lobes were involved without
sparing of the costophrenic angles (Figure 1) Fiberoptic
bronchoscopy showed no abnormalities. PFTs, obtained
one month post-operation, revealed a mild obstruction with
reversible to bronchodilator of 12% and 420mL improvement
in FEV1% (Figure 2); FEV1, 2.27L (60% of predicted);
FEV1/FVC ratio, 70.9%; residual volume (RV), 2.54L (222%
of predicted); total lung capacity (TLC), 5.83L (104% of
predicted); RV/TLC, 43% of predicted normal; and diffusing
capacity of the lung for carbon monoxide (DLco), 22.3
mL/mmHg/min (72% of predicted). MCTs demonstrated
bronchial hyperresponsiveness (BHR) (PD20 FEV1o8mg/ml).
Thoracotomy was performed to obtain a biopsy specimen
(Figure 3), bleblectomy and pleurodesis. The lung biopsy
showed a densely cellular infiltrate of histiocytes and other
inflammatory cells within the interstitial and airspaces
(Figure 4). Corticosteroid in addition to a combination of
inhaled corticosteroid and long-acting b2 agonist was
administered as a maintenance therapy for controlling PLCH
and BHR. The patient was doing well after 1-month of
follow-up.
Discussion
PLCH has an unpredictable course and can cause significant
pulmonary impairment owing to its complications.2–4 The
most common presenting symptoms are cough, exertional
dyspnea and constitutional symptoms. Other uncommonsymptoms include chest pain, pneumothorax and hemopty-
sis.3,4,6 Chest examinations may reveal normal, rhonchi,
wheezing, or decrease breath sounds. The interval between
the onset and the diagnosis is highly variable with an
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Figure 3 Surgical lung biopsy specimen by wedge resection method demonstrates bullae at the apex of the right lung.
Figure 4 High-power photomicrograph (hematoxylin and
eosin,  600) of the surgical lung biopsy showed a densely
cellular infiltrate of histiocytes and other inflammatory cells
within the interstitial and airspaces and the characteristic
pulmonary Langerhans cells histiocytosis of abundant pale,
eosinophilic cytoplasm with typical delicate and folded nuclei
(positive CD1a and S-100 protein) (straight arrow) and scattered
interspersed eosinophils along the wall of the alveolar ducts and
alveoli.
Pulmonary Langerhans cell histiocytosis 63average of 6 months (range: a few days and 5 years).4 In our
patient, the age at onset of his symptoms and the diagnosis
was 10 years and 18 years, respectively.
Pulmonary function tests in PLCH are variable. It may
be normal in 10–15% whereas some show only a little
impairment despite extensive radiological changes. Typi-
cally, obstructive dysfunction in PLCH is associated with
worsening of the cystic lesions, which coalesce into bullae inadvanced stage. Owing to cellular aggregation and en-
croachment of distal bronchioles, it can cause small airways
luminal narrowing with associated air trapping and second-
ary lung cyst formation. It appears to correlate with the
extent of the HRCT abnormalities and exercise limita-
tion.3,4,7 In advanced stage of the disease, PFTs may show
restrictive or combination. The most consistent abnormality
of lung volume study is the reduction of DLco. The degree of
airway obstruction seems to be out of proportion of the total
cigarette consumption and should reflect the predominantly
bronchiolar involvement of PLCH.3,4 Our patient is non-
smoker. Reversible obstructive changes on his PFTs and
positive MCT accompanying a response to the asthmatic
medications should suggest asthma as a comorbid disease.
BHR defined as an exaggerated bronchoconstrictor re-
sponse to a wide variety of stimuli that generally elicits
little or no response in a normal individual. This entity
could be found in healthy adult up to 27%.8 Recently, it was
found to be associated with the development of respiratory
symptoms, an increased annual loss of FEV1, asthma and
COPD.9 Only one study5 described the patients, demonstrat-
ing significant bronchial hyperreactivity to carbachol than
the controls. However, there has never been a study,
describing PFTs including MCT on the patients with PLCH.
Most common chest radiograph are peribronchiolar micro-
nodular and interstitial infiltration, with a predominance of
middle- and upper-lobe involvement. Characteristically, HRCT
also reveals nodular abnormality accompanied by cystic
changes, predominantly at the same areas.4 It is usually
bilateral and symmetric involvement. In later stages, cystic
changes may become more prominent and can coalesce into
bullae with honeycombing appearance.4 However, the dis-
tribution of lung cysts in our patient did not spare the lower
lung base and costophrenic angles as the typical patterns. This
process may be accelerated by an air trapping of BHR.
Considering PLCH is a smoking-related interstitial lung
disease and progressive cystic changes that predispose to
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nodules with or without cavitation, hyperinflation in addition
to probable asthma in our patient could contribute to the
scattered large bullae and spontaneous pneumothorax
(Figure 1).2,6 Pneumothorax can occur as the initial manifes-
tations of PLCH in 11% with the reported incidence between
4% and 17%. Some authors recommend the interventions since
the first episode of pneumothorax, particularly in the case of
low surgical risk owing to the higher recurrent rate of
secondary spontaneous pneumothorax (11–79%).6
To date, there is no standard treatment for PLCH. Several
patients resolve spontaneously with smoking cessation
alone. Corticosteroid has been the mainstay treatment for
symptomatic PLCH whereas combined chemotherapy is
administered in severe multisystemic LCH. In case of rapid
deterioration and development of respiratory failure, lung
transplantation should be considered.3,4 Administration of
corticosteroid in addition to a combination of inhaled
corticosteroid and long-acting b2 agonist improved his
symptoms with a much improved quality of life. Physicians
should consider this disease even in nonsmokers.
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